Abstract Schizophrenia is a heterogeneous, debilitating disorder characterized by three distinct sets of clinical features: positive symptoms, negative symptoms, and cognitive deficits. Extant antipsychotic drugs have been most successful at treating the positive symptoms of patients with schizophrenia but have minimal therapeutic effects on negative symptoms and cognitive deficits, which are the symptoms that best predict the poor prognosis of these patients. Therefore, there has been a major effort towards identifying compounds that alleviate these symptoms. Oxytocin (OT) is a nonapeptide that regulates peripheral reproductive-relevant functions, and also acts as a neurotransmitter in the brain. Converging evidence from both preclinical and clinical research suggests that OT may have therapeutic efficacy for the positive symptoms, negative symptoms, and cognitive deficits of schizophrenia. In the majority of the small, randomized, placebo-controlled clinical trials conducted to date, OT has shown particular promise in its potential to treat the intractable negative symptoms and social cognitive deficits exhibited by most of the patients with this debilitating disorder. In this leading article, we summarize the clinical evidence relevant to (1) endogenous OT and schizophrenia, and (2) the putative therapeutic effects of OT on each of the three clinical domains.
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Key Points
Current antipsychotic drugs have produced their greatest benefit in treating the positive symptoms of schizophrenia but have limited therapeutic effects on the negative symptoms and cognitive deficits in patients with this devastating disorder.
The convergent findings from recent small clinical trials and studies of the endogenous oxytocin system in patients with schizophrenia are encouraging, although not completely consistent. Together, they suggest that oxytocin may reduce the currently treatment-resistant debilitating negative symptoms and social cognitive deficits, as well as the positive symptoms.
Despite these encouraging preliminary findings, many issues still need to be addressed while optimizing oxytocin or oxytocin-mimetics to alleviate symptoms of schizophrenia.
people with SCZ also exhibit deficient cognitive processing, further impairing their ability to function. Seven specific domains of cognitive impairment were identified by the National Institute of Mental Health (NIMH) Measurement and Treatment Research to Improve Cognitive Symptoms in SCZ (MATRICS) initiative in patients with SCZ including working memory, attention/vigilance, visual and verbal learning and memory, information processing speed, reasoning and problem solving, and social cognition [1] . Although positive symptoms are required for a diagnosis of schizophrenia, a subset of patients do not exhibit negative symptoms and/or cognitive deficits consistent with substantial clinical heterogeneity among patients meeting the diagnostic criteria for SCZ [2] .
When taken consistently by patients with SCZ, current antipsychotic drugs (APDs) provide substantial relief from the positive symptoms. These drugs bind and reduce neural transmission through D2 receptors in the mesolimbic pathway [3] . Whereas this is considered the sole mechanism of action for first generation or 'typical' APDs (e.g., haloperidol), second generation atypical APDs (e.g., clozapine) have an additional mechanism via high receptor occupancy of serotonin-2A receptors at therapeutic doses [4] and these newer APDs are associated with reduced extrapyramidal side effects and possibly modest increased efficacy against negative symptoms and cognitive deficits [4] [5] [6] [7] [8] [9] . Unfortunately, current APDs have, at best, produced minimal therapeutic effects on the negative symptoms and cognitive deficits associated with poor functioning and prognosis [10, 11] . Therefore, the development of medications aimed at alleviating the negative symptoms and cognitive deficits of SCZ, highly chronic disabling symptoms of this disorder, are of highest priority.
Recently, converging results from preclinical and clinical studies suggest that activation of the oxytocin (OT) system may produce therapeutic effects on all three symptom domains of SCZ. Of relevance to its potential therapeutic effects in SCZ, OT exhibits neurotransmitter activity in the brain and recently has become strongly associated with positive regulation of affiliation and social cognition, in addition to its role in learning and memory, and stress [12] . Additionally, dopaminergic and serotoninergic neurotransmission also contribute to the regulation of motivated behaviors [13] . In fact, the rewarding properties of social interaction in mice are dependent on the coordinated interaction of OT and serotonin in the nucleus accumbens [14] , and OT interactions with the dopaminergic system facilitate higher social-cognitive functions [15, 16] .
In this article, we summarize clinical studies aimed at investigating (1) endogenous OT and SCZ, and (2) the potential for OT or OT-mimetics to provide relief from the positive symptoms, negative symptoms, and the cognitive deficits that torment patients with this devastating disorder.
To identify the studies described in this review, we performed PubMed keyword searches with OT and either SCZ, positive symptoms, negative symptoms, or cognitive deficits.
The Role of Oxytocin (OT) in the CNS
OT is a nine-amino acid peptide that is highly conserved across a wide variety of species [17, 18] and is best known for its role in regulating peripheral reproductive-relevant functions such as uterine contractions in parturition and lactation [19, 20] . In the mammalian brain, OT is also both a neurohormone and a neurotransmitter [19, [21] [22] [23] . It is structurally very similar to its sister peptide vasopressin, differing by only two amino acids in humans. OT is synthesized in distinct neurons in the paraventricular and supraoptic nucleii from where it is delivered by hypothalamo-neurohypophyseal fibers to capillary spaces in the posterior pituitary. OT circulates unbound to proteins in blood where it produces its hormonal actions [18, 24] .
OT also acts as a peptide neurotransmitter in the brain. However, the mechanisms of its central action differ somewhat from those of classical neurotransmitters. For example, in contrast to classic neurotransmitters, OT produces its effects via both axonal release from parvocellular neurons in the hypothalamic paraventricular nucleus into specific brain regions such as the nucleus accumbens and amygdala, as well as through somatodendritic release into the CSF and subsequent diffusion (volume effects) in the brain [14, 25] . Neuropeptides such as OT, unlike neurotransmitters, do not have a reuptake system and can produce a variety of effects via short-range diffusion in CSF and extracellular fluid [21, 26] .
OT receptors have been localized to several brain regions associated with SCZ including subregions of the basal ganglia, central nucleus of the amygdala, substantia nigra, and lateral septal nucleus [27] [28] [29] . In addition to its binding and subsequent action via the oxytocin receptor (OXTR), OT also has lower but functionally significant affinity for vasopressin receptors, including the arginine vasopressin receptor 1A (AVPR1A) (the AVPR most abundant in brain) and AVP1B receptors [30] . In fact, OT binding to AVPR1A can contribute to OT's CNS relevant effects [31] , and sometimes is solely responsible [32, 33] . In clinical or preclinical studies related to SCZ spectrum disorders, the relative role of OXTR versus AVPRs has not been well elucidated. Readers should take note that the experimental effects of OT described in this article may be mediated by OXTR, one of the AVPRs, or both.
The functional significance of OXTRs in the brain was brought to light by Insel et al. [34] , who found that the distribution and density of OXTRs in the ventral striatum (nucleus accumbens) contributed to contrasting social attachment styles (monogamous vs promiscuous) in voles. This finding has significant translational relevance as differential distribution and density of OXTRs in rewardrelevant brain regions in humans may help to explain individual differences in social attachment behaviors. Also consistent with a functional role for OT in social rewardrelevant brain regions, Dolen et al. [14] , using an oxytocin antagonist, demonstrated that OT acts as a social reinforcement signal within the nucleus accumbens core in mice, where it elicits presynaptically expressed long-term depression of excitatory synaptic transmission in medium spiny neurons. This study also established a key role for serotonergic transmission via 5-HT1B receptors in the nucleus accumbens, in the processing of OT-mediated social reward [14] .
Converging evidence suggests that OT interacts with several neurotransmitter systems in the brain, including dopamine (DA) [35] [36] [37] , glutamate [38] [39] [40] , and serotonin [41] , to produce some of the behavioral effects produced by APDs, such as facilitation of prepulse inhibition (PPI) [42] . The preclinical studies supporting these interactions are described briefly in the next section and reviewed in detail elsewhere [43] .
Preclinical Models of OT and Schizophrenia
Animal models of relevance to SCZ have limitations in their ability to model the disorder, especially the positive symptoms such as hallucinations and delusions. However, animal models have been an invaluable tool for identifying novel compounds with APD potential. In addition, animal models allow investigators to utilize powerful techniques that would be too invasive (e.g., in vivo brain sampling) in humans. A variety of animal models have been utilized to investigate the potential therapeutic-like effects of OT against all three symptom domains of SCZ.
Here we provide a brief review of animal models that provide insight into the potential mechanisms underlying the therapeutic effects of OT against the positive symptoms, negative symptoms, and social cognitive deficits. Animal models relevant to the effects of OT on the three domains of SCZ have been reviewed in more detail elsewhere. Please see Feifel et al. [43] for a recent review.
Converging preclinical evidence that OT may counteract central hyperdopaminergia and hypoglutamatergia [12, 38, 42] is consistent with the potential of OT to alleviate the positive symptoms of SCZ. For example, Feifel et al. [42] reported that OT reversed PPI deficits produced by the indirect DA agonist, amphetamine, and the noncompetitive glutamate antagonist, MK-801, but not the direct DA agonist, apomorphine. These results suggested that OT produced antipsychotic-like drug effects by acting presynaptically on DA neurons to inhibit DA release. This mechanism of DA inhibition complements the primarily postsynaptic inhibition of DA D2 receptors produced by APDs and may explain why adjunctive OT is able to improve positive symptoms beyond the therapeutic effects of current APDs [43, 44] .
It appears that the most beneficial therapeutic effects of adjunctive OT are against the negative symptoms and social cognitive deficits of SCZ for which current APDs exhibit little or no therapeutic benefit. Consistent with its therapeutic effects on the negative symptoms, Dolen et al. found that in mice the rewarding properties of social interaction were dependent on the coordinated interaction of OT and serotonin in the nucleus accumbens [14] .
Multiple studies have found that OT improves social cognition in animal models, which is consistent with the results from most clinical trials [43, 44] . In this respect, OT interacts with dopaminergic circuitry enhancing the attribution of salience to social and emotional stimuli, while facilitating higher social-cognitive functions [15, 16] .
Endogenous OT and Schizophrenia
Evidence for an inverse relationship between plasma OT (pOT) levels and symptom severity suggests that OT may contribute to the etiology of SCZ. For example, low pOT levels have been associated with more severe symptoms in all three domains of SCZ, although these findings have been most consistent for the negative symptoms and cognitive deficits [43] . However, it is not completely clear if this relationship is causal, a consequence of the disease or a response to APD treatment. In addition, there is controversy regarding the relevance of peripheral OT to OT in the CNS. Some reports do not support a relationship between CSF OT concentrations and pOT levels, bringing into question the potential relevance of peripheral OT levels to the behaviors of interest [45, 46] ; but see [47] and for reviews see [26, 48] .
In regard to the positive symptoms, there have only been a few reports and the findings have not been completely consistent. For example, female patients who had less severe positive symptoms and overall pathology also had higher pOT levels [49] (Table 1 ). In contrast, the same group reported more recently that more severe positive symptoms were related to higher pOT [50] . In a genetic study, Souza et al. [51] reported that variants in the OXTR gene rs11706648, rs4686301, rs237899 were nominally associated with positive symptoms. Functionality of these three single nucleotide polymorphisms (SNPs) has not been reported. Keri et al. [55] Vide supra pOT CTL subjects exhibited elevated pOT after trust-related interactions, whereas SCZ subjects did not Suggests a defect in OT system's ability to respond to interactions promoting trust consistent with OT effects on facial affect recognition [78, 81, [85] [86] [87] [88] Rubin et al. [49] Vide supra pOT In both sexes, patients with higher pOT exhibited more prosocial behaviors (PANSS)
Suggests endogenous OT promotes pro-social behavior
Rubin et al. [63] 48 SCZ (26 M, 22 F) 57 CTL pOT Higher pOT related to perceiving faces as happier in both female patients and CTL Sex differences reported in other studies of pOT [115, 116] and in [117] but not other studies of IN OT [118, 119] Rubin et al. [68] Vide supra pOT pOT unrelated to cognition in SCZ As opposed to the positive symptoms, many studies have addressed the relationship between the severity of negative symptoms and pOT levels and they have consistently found an inverse relationship between the severity of negative symptoms and levels of pOT and OT levels in CSF. For example, Jobst et al. [52] and Sasayama et al. [53] reported more severe negative symptoms were related to lower pOT and lower CSF OT levels, respectively. In a more recent study, Strauss et al. found that the severity of asociality in patients with SCZ can be predicted by lower pOT levels [54] . Consistent with these findings, Keri et al. reported that flattened affect and social withdrawal may be associated with decreased trust-related OT levels in SCZ [55] . Several genetic studies have provided further support that the OT system may contribute to the negative symptoms of SCZ. For example, in 2010 Souza et al. [51] reported nominal association with the negative symptoms in patients with SCZ and an OT T/G gene variant (rs2740204). This SNP is located in the promoter of the OT/vasopressin genes and functionality of this SNP is suggested by its association with OT expression levels in bipolar subjects. However, this association was not detected in a SCZ sample [56] , suggesting the described functionality may not be relevant to the etiology of SCZ. More recently, Montag et al. detected a significant association with negative symptom scores (Positive and Negative Symptoms Scale [PANSS]) and OXTR variant rs237902 (GG [ AA) [57] . This SNP results in an amino acid change-asparagine to lysine-but more work is necessary to determine if this amino acid change affects OXTR function. Furthermore, Haram et al. [58] found significant association between emotional withdrawal and the OXTR gene variant rs53576 (A allele). This SNP affects functions in healthy individuals of potential relevance to the negative symptoms [59] [60] [61] . For example, AG and GG alleles were associated with lower striatal DA transporter availability compared with the AA allele [59] .
Relevant to cognition, higher pOT levels have been associated with enhanced social cognition including more prosocial behavior in males and females [49] , superior emotion recognition [62] , and perception of faces as happier by female SCZ and controls [63] . Also consistent with a role for endogenous OT in social cognition, higher pOT levels in patients with SCZ were associated with more avoidance of angry faces in an Approach-Avoidance task [64] , better emotion recognition in controls and SCZ (females only) [65] , and more accurate encoding of socially relevant information in SCZ [66] . Although they did not detect differences in pOT levels between SCZ and controls, Frost et al. reported that in addition to social cognition, superior processing speed and working memory were also associated with higher levels of pOT [67] . However, Rubin et al. reported that OT levels in patients with SCZ were not related to clinical symptoms or cognition [50, 68] .
Findings from genetic studies have also consistently detected endogenous OT as a potential contributor to social cognitive deficits. In this respect, worse social perception, mentalizing and poorer performance on a social cognition index in patients with SCZ were significantly associated with an OXTR (rs2268493) T variant [69] . T/T homozygotes exhibited decreased activation in the mesolimbic reward circuit (functional magnetic resonance imaging [fMRI]) during anticipation of rewards [70] , which appears to be more relevant to negative symptoms than to social cognition. Furthermore, the OXTR variant (rs2254298) was significantly associated with empathic concern (A [ GG) [71] . Regarding functionality, A allele carriers demonstrated deficient deactivation of anterior cingulate gyrus (ACG) during emotional processing [72] . More work is necessary to determine if deactivation of the ACG is relevant to empathic concern.
Therapeutic Effects of Exogenous OT on Schizophrenia
Initially a potential role for OT in alleviating the positive symptoms of SCZ was supported by the converging preclinical evidence that OT may counteract central hyperdopaminergia and hypoglutamatergia [38, 42] . In subsequent studies in healthy subjects, administration of a single intranasal (IN) dose of OT was reported to enhance trust of strangers by healthy subjects [73, 74] . More recently, several small clinical trials designed primarily to investigate the potential of IN OT to reduce SCZ symptoms have been published. However, each of these studies has investigated IN OT as an add-on to standard APDs or non-pharmacological treatments aimed at improving social behavior. Thus, the gold standard approach to assessing the efficacy of a putative drug, a monotherapy randomized, controlled clinical trial, has yet to be conducted, limiting the ability of the field to truly determine the inherent therapeutic properties of OT for SCZ.
To date, four small clinical trials designed primarily to investigate the potential of IN OT as an adjunct medication to stable doses of APDs to further attenuate psychosis in SCZ have been published (see Table 2 for a summary of OT clinical trials in SCZ). In the initial clinical trial, Feifel et al. performed a clinical proof-of-concept study of the therapeutic potential of OT by employing a randomized, double-blind, placebo-controlled crossover design. IN OT given twice daily to patients with SCZ for 3 weeks significantly decreased positive subscale scores on the PANSS [75] . The clinical significance of their findings was Adapted from Feifel et al. [43] Several decades ago, investigators in the USSR published two letters [130, 131] describing open-label experience using OT to treat patients with ''SCZ'' and a small randomized study [132] of OT in ''SCZ'' subjects. These reports suggested that OT had therapeutic effects. However, these reports contain clinical descriptions and terminology that do not correspond to contemporary concepts of SCZ. Furthermore, the rigor of methodology and reporting is well below accepted current standards. These shortcomings significantly limit the value of these early reports to shed light on the effects of OT in SCZ [77] . In a clinical trial by Pedersen et al. [78] , twice daily IN OT given to patients with SCZ for 2 weeks significantly reduced the PANSS positive subscale scores compared with IN placebo and produced a nearly significant reduction in the PANSS negative subscale (p \ 0.08). This treatment regimen also improved cognitive deficits; that is, identification of second false beliefs and trends toward significant improvement in accurate recognition of deception and rating untrustworthy faces as trustworthy (Brune task). Modabbernia et al. [79] , in the largest human trial to date, reported that administration of twice daily IN OT to patients with SCZ for 8 weeks significantly improved PANSS total, positive, and negative subscores as early as 4 weeks after the initiation of OT treatment.
BPRS
In the fourth trial, Lee et al. [80] did not detect a significant change in Brief Psychiatric Rating Scale (BPRS) in patients with SCZ after administration of twice daily IN OT for 3 weeks. These negative findings, which were not consistent with the first three clinical trials, could be related to the use of the BPRS. The overall score of this 18-item scale represents a summation of various aspects of psychosis. The 30-item PANSS, considered the gold standard in SCZ research, was used in the three studies reporting positive findings. In contrast to the BPRS, the PANSS items are readily categorized into separate subscores for positive, negative, and general symptoms of SCZ. In contrast to their negative findings on the therapeutic effects of OT on positive symptoms, Lee et al. [80] found that negative symptoms improved in a small group of patients, 3 weeks after the start of OT treatment (Scale for Assessment of Negative Symptoms [SANS]). Neither Lee et al. [80] nor Modabbernia et al. [79] investigated the effects of OT on cognitive deficits.
Three additional clinical trials also measured changes in psychosis but as a secondary measure. These studies were designed to investigate the effects of IN OT on social cognition in SCZ. In the first of these studies, Gibson et al. [81] found no improvement in PANSS positive scale scores after 6 weeks of twice daily IN OT compared with IN placebo. On the other hand, OT reduced fear recognition and the perspective-taking component of empathy (ER-40), as well as PANSS negative subscale scores.
Based on converging evidence consistent with OT's potential as a cognitive enhancer [82] , the benefits of OT added to a potent psychosocial treatment have been investigated by a couple of research teams. For instance, Cacciotti-Saija et al. [83] reported that adding twice-daily IN OT or IN placebo to 6 weeks of social cognitive training (SCT) in patients with early psychosis did not increase the positive effects of SCT beyond the effects of placebo. They also found no improvement of positive symptoms (measured with the Scale for the Assessment of Positive Symptoms [SAPS] ) beyond the SCT alone [83] and daily OT added to SCT did not add to the improvement in SANS scores after placebo. However, there was a positive correlation between the reduction of negative symptoms as measured by the SANS and the volume of IN OT (total number of OT IN treatments) but not placebo, administered by patients with SCZ. In the second study, Davis et al. [84] reported that OT given just before twice weekly sessions of a 6-week SCT enhanced social cognitive benefits greater than placebo and this improvement in empathic accuracy lasted at least 1 month. However, they did not detect improvement in BPRS or negative symptoms (Clinical Assessment Interview for Negative Symptoms [CAINS]) beyond those produced by SCT alone. As in all the studies reviewed here, these contrasting results may be due to different dosage or duration of OT treatment employed (see study details in Table 2 ), highlighting the great need for more studies aimed at identifying the optimal dose and time course of OT treatment.
In addition, a single dose of IN OT has been reported to enhance performance of patients with SCZ on many social cognitive tasks including deception, sarcasm, recognition of emotion, and empathy [85] [86] [87] [88] [89] [90] . The effects of IN OT on social cognition in healthy subjects are reviewed in Evans et al. [91] . In these studies, a single administration of IN OT consistently enhanced the processing of social stimuli.
Recently, Shin et al. [92] in the first report of OT effects on neural activity associated with social cognition (facial emotion recognition) in SCZ found that a single dose of IN OT increased activity (fMRI) for happy faces while decreasing amygdala activity for fearful faces. These results are consistent with many other reports of alterations in amygdala activity in normal controls during emotional recognition tasks [93] .
While direct proof that IN-administered OT enters the brain is lacking, several recent reports provide unequivocal evidence that IN OT invokes increased OT levels in the CNS of humans [94] , primates [95] , and rats [96] , whether it be by the exogenous peptide entering the CNS or by stimulation of endogenous OT release in the CNS. CSF OT levels in human and monkeys peaked 35-75 min after IN OT administration and OT levels in rats peaked in the hippocampus and amygdala 30-60 min after IN OT administration. Although IN OT produces elevated OT levels in the CNS, it is still possible that some of the therapeutic effects of IN OT are mediated through peripheral regulation of central OT since IN OT also elevates plasma OT levels [94] , mainly via stimulation of endogenous OT release in the periphery. Elevated plasma OT could indirectly modulate therapeutic effects in the brain by, for example, binding to OXTRs in the vagus nerve [97] , thereby producing central effects via vagal projections to the hypothalamus.
In summary, the robust ability of OT to facilitate trust toward strangers provides a potential mechanism for its therapeutic action on paranoid delusions (positive symptom). OT reduced positive symptoms in three out of four clinical studies designed to measure the effects of IN OT on psychosis in SCZ. However, OT improvement of positive symptoms was not detected in three other studies aimed at testing the ability of OT to enhance social cognitive training or to improve social cognition. Importantly, six of the seven clinical studies that measured the effects of OT on negative symptoms provided evidence that OT may reduce negative symptoms. In the lone study that did not provide such evidence, Davis et al. [84] , the lack of an effect of OT on the negative symptoms could have been due to the minimal OT treatment regimen (two times per week), in contrast to the daily OT treatment regimen used in the other six studies. It is noteworthy that in contrast with several animal studies [98] [99] [100] [101] , where chronic OT administration produced either no benefit or exacerbation of social interaction in rodents, these clinical studies reveal very promising effects of chronic daily OT on negative symptoms. Finally, both acute and chronic OT administration has consistently improved social cognition in both controls and patients with SCZ.
Conclusions
Patients with SCZ desperately need more effective treatments, especially for the negative symptoms and cognitive deficits that are incompletely treated by current APDs. The findings described in this review from the recent small, randomized, double-blind, placebo-controlled, add-on clinical trials and studies of the endogenous OT system in patients with SCZ are encouraging, though not completely consistent. Together, they suggest that OT may reduce the currently treatment-resistant debilitating negative symptoms and social cognitive deficits, as well as the more treatment-responsive positive symptoms. IN OT produced no significant adverse effects and was well tolerated across clinical studies. Despite these encouraging preliminary findings, many issues still need to be addressed while optimizing OT or OT-mimetics to alleviate symptoms of SCZ-spectrum disorders.
The extant clinical trials collectively do not represent an adequate test of the therapeutic potential of OT for SCZ. For example, each trial has been small and only one dose of OT (range 48-80 IU/day) was administered as an adjunct therapy to already stable regimens of APDs. Therefore, the optimal time course, therapeutic OT dose, and dosing regimen for optimal treatment of all three clinical domains of SCZ has yet to be identified.
Significant limitations are inherent to add-on trials (see [102, 103] ), and especially problematic is their inability to test the hypothesis that the added drug is an effective treatment for the clinical disorder of interest. Add-on trials are limited to testing whether the add-on drug plus the primary drug are more effective than the primary drug alone. Of particular concern were studies in which OT was given as an adjunct to non-pharmacological interventions such as social cognition training, while patients were also on stable regimens of APDs, making it even more difficult to detect a therapeutic effect of OT.
The inclusion criteria, which requires that patients exhibit significant symptoms (i.e., PANSS score) after being stabilized on an established APD, is another serious limitation of the add-on study designs for IN OT in SCZ. These subjects at best have had an incomplete response to the primary treatment (APDs), and at worst, no response to the primary treatment. The incomplete responders will have decreased symptoms at baseline and, therefore, a limited range of symptoms to exhibit improvement to the add-on therapy compared with untreated patients (ceiling effect). As non-responders are often treatment resistant, they are less likely to respond to any drug treatment compared with most patients with SCZ. As expected, drugs that have been tested as both add-ons and as monotherapy reveal less therapeutic effect sizes as add-on medications (e.g., [104] ).
The gold standard approach to assessing the efficacy of a putative drug, a monotherapy randomized, placebo-controlled clinical trial, has yet to be conducted, limiting the ability of the field to truly determine the inherent therapeutic properties of OT for SCZ. The optimal clinical utility of OT for SCZ may ultimately be as an adjunct to conventional APDs as it may not possess sufficient efficacy on some of the core features of this disorder (e.g., positive symptoms) to be used as a monotherapy alternative to conventional APDs. However, in order to effectively characterize the inherent potential clinical effects of OT for the various clinical features of SCZ, a monotherapy trial of OT in SCZ needs to be conducted.
Although it would be optimal to perform OT monotherapy clinical trials designed to investigate the therapeutic efficacy of OT against SCZ, it is unlikely that many institutional review boards (IRBs) will approve outpatient placebo-controlled monotherapy trials of an investigational drug in subjects with SCZ. Regarding OT, IRBs are especially cautious since its mechanism of action remains to be fully elucidated and APD monotherapy trials usually require hospitalization of subjects, at least during the initial study phase and during the drug washout [105] . In this respect, gaps in our knowledge about the drug properties of OT, described above and in more detail in a previous paper [106] , should be elucidated before conducting a monotherapy trial.
An adequately powered test of the efficacy of OT as an adjunct to APDs would require a larger sample size than an OT monotherapy trial due to the reduced effect size associated with add-on studies. Considering the previously described limitations inherent in their add-on design, and administration of only one OT dose and small sample sizes, it is very promising that three out of four clinical trials designed to test the anti-psychotic effects of OT found that OT exhibited therapeutic efficacy against the positive symptoms of SCZ [75, [78] [79] [80] . It is also not very surprising that three recent studies designed to specifically investigate the therapeutic effects of OT on social cognition did not detect improvement in positive symptoms or negative symptoms. The most encouraging results suggest that OT consistently had therapeutic effects on negative symptoms and cognitive deficits, the symptoms most in need of effective treatments. In this respect, six out of seven small clinical trials found evidence that OT had some therapeutic efficacy against the negative symptoms and social cognitive deficits. The lone study that failed to detect any therapeutic effects of OT against cognitive deficits was unable to detect an OT improvement in cognitive deficits beyond the improvement produced by social cognition training alone.
Therapeutic effects of OT consistent with some of the findings reviewed here could provide much needed hope to patients with SCZ and their families that OT may provide relief, especially from the poorly treated and debilitating negative symptoms and cognitive deficits. The effective treatment of these symptoms by OT would likely lead to improvement in the poor prognosis characteristic of this disorder, hopefully allowing those with SCZ to lead more fulfilling lives.
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